Enzymes, trophoblasts, and cancer: the afterlife of an idea (1924-2008)

Area of Science:

• Oncology
• Biochemistry
• Complementary and Alternative Medicine

Background:

• John Beard pioneered enzyme therapy for cancer in the early 20th century.
• Despite initial efforts and international interest between 1905-1911, Beard's approach did not gain widespread acceptance.
• Subsequent American researchers, including McDuffie, Morse, Shively, and Kelley, continued investigating enzyme-based cancer therapies throughout the 20th century.

Observation:

• Pancreatic enzyme use as an adjuvant cancer treatment is common in complementary and alternative medicine (CAM) globally.
• This therapeutic approach is recognized for its anti-inflammatory properties.
• It is also utilized to alleviate adverse effects associated with cytotoxic cancer treatments.

Findings:

• Early 20th-century enzyme therapy research, led by John Beard, did not achieve mainstream clinical adoption.
• Ongoing research by various scientists has sustained interest in enzyme-based cancer treatments.
• Current CAM practices incorporate pancreatic enzymes for cancer support and managing treatment side effects.

Implications:

• Enzyme therapy represents a persistent area of interest within cancer research and complementary medicine.
• The continued use of pancreatic enzymes suggests a perceived benefit in managing cancer and its treatment's side effects.
• Further research may elucidate the mechanisms and optimize the application of enzyme therapy in oncology.